Partnerships

Our health care system is complex. There are many key decision makers at either federal, national or provincial levels that are responsible for the health care services Canadians receive from coast to coast. Myeloma Canada has partnered with other patient organizations and coalitions to drive change towards a more favourable patient-focused environment.

Our growing network of partners includes:
 

Provincial (QC)

• Alliance des patients pour la santé
• Catalis Clinical Trials Québec
• Clinical Research in Oncology (Q-ROC)
• Coalition Priorité Cancer
• Fondation québécoise du cancer
• Groupe des maladies plasmocytaires du Québec (GMPQ)
• Institut national d’excellence en santé et services sociaux (INESSS)
• Quebec Plasma Cell Dyscrasia Group
• Regroupement des organisations communautaires en oncologie (ROCO)
• Victimes des pesticides du Québec

National & International

• All.Can Canada
• Canadian Agency for Drugs and Technologies in Health (CADTH)
• Canadian Association for Healthcare Reimbursement
• Canadian Myeloma Research Group (CMRG)
• Canadian Organization for Rare Disorders (CORD)
• Cancer Action Now
• CanCertainty Coalition
• CONECTed (Collective Oncology Network for Exchange, Cancer Care Innovation, Treatment Access and Education)
• Global Myeloma Action Network (GMAN)
• Health eMatters
• Innovative Medicines Canada
• International Myeloma Foundation (IMF)
• Myeloma Alberta Support Society (MASS)
• Myeloma Patients Europe (MPe)
• Myeloma Patients Europe (MPe) Community Advisory Board
• PDCI
• Patented Medicine Prices Review Board
• Real World Evidence (RWE) 4 Decisions
• Santis
• Southern Alberta Myeloma Patient Society (SAMPS) International
• Wellspring

Pharmaceutical partners

• Abbvie
• Amgen
• Apotex
• AstraZeneca
• Binding Site
• Bristol Myers Squibb
• Forus Therapeutics
• GlaxoSmithKline
• Janssen
• Merck
• IMC
• Pfizer
• Rapid Novor
• Roche 
• Sanofi
• Sebia Diagnostics 
• Takeda 
• Telo Genomics